Skip to content

Ceva CEVA License — Revenue

Other product segments

Royalty
$9.2M0.0%

Similar metrics at other companies

Dianthus Therapeutics logo
DNTHLicense — Revenue
$463K-60.2%
Eton Pharmaceuticals, Inc. logo
ETONLicense — Revenue
$0-100%
Nuvation Bio logo
NUVBLicense — Revenue
$64.72M+1,999%
BioCryst Pharmaceuticals logo
BCRXLicense — Revenue (Gross)
$3.02M
Mannkind logo
MNKDLicense And Service — Revenue
$23.52M-20.0%
AnaptysBio, Inc. logo
ANABLicense — Revenue
$0-100%

Other financials

Income statement

See full
Revenue$27.0M+11.5%
Gross profit$23.3M+12.2%
Operating income-$5.1M-16.0%
Net income-$4.5M-34.0%
EPS (diluted)-$0.21-200%

Balance sheet

See full
Cash & equivalents$21.4M+13.6%
Total debt$16.9M+249%
Total equity$338.2M+25.7%
Total assets$388.2M+25.2%

Cash flow

See full
Operating cash flow-$4.9M+34.0%
CapEx$2.3M+644%
Free cash flow-$7.2M+6.7%

Valuation

See full
Market cap$1.25B+154%
Enterprise value$1.25B+161%
P/S11.2×+6.6×

Profitability

See full
Gross margin89.9%
Operating margin-0.3%
Net margin-10.5%+26.2pp
FCF margin1%

Returns & leverage

See full
Return on equity-3.9%+4.7pp
Debt / equity0.0×
Current ratio10.3×+2.8×

Where this comes from

Reported directly by Ceva in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ceva’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ceva's license — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ceva's license — revenue?
Ceva (CEVA) reported license — revenue of $17.82M in Q1 2026.
What does license — revenue mean?
This metric represents the net revenue recognized from licensing intellectual property and related services within the specific business segment, excluding any assessed taxes. It serves as a primary indicator of the underlying demand for the company's proprietary technology and the effectiveness of its licensing business model. By isolating net revenue, it allows investors to assess the core commercial performance of the segment without the distortion of tax-related accounting variations.